Aprea Therapeutics (NASDAQ:APRE – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.15 million for the quarter.
Aprea Therapeutics Stock Performance
Shares of Aprea Therapeutics stock opened at $2.39 on Monday. The stock has a 50 day moving average of $3.18 and a 200 day moving average of $3.27. The firm has a market capitalization of $12.99 million, a price-to-earnings ratio of -0.85 and a beta of 0.82. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $6.80.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Wednesday, January 15th.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Recommended Stories
- Five stocks we like better than Aprea Therapeutics
- Manufacturing Stocks Investing
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Investing In Automotive Stocks
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
